Stifel analyst Rick Wise raised the firm’s price target on Johnson & Johnson to $220 from $205 and keeps a Hold rating on the shares following the company’s Q4 sales outperformance and above-consensus initial 2026 guidance.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $250 from $240 at Goldman Sachs
- Johnson & Johnson price target raised to $221 from $220 at BofA
- Johnson & Johnson price target raised to $250 from $232 at Citi
- Johnson & Johnson price target raised to $240 from $230 at Wells Fargo
- Johnson & Johnson: Solid Fundamentals but Fully Valued with Litigation Overhang Supporting Hold Rating